Friday, June 23, 2017

Nature Reviews Cancer contents July 2017 Volume 17 Number 7 pp393-440

If you are unable to see the message below, click here to view.

Nature Reviews Cancer

Discover What's Driving Tumor Cell Biology

Cancer cells reprogram their metabolism to generate the energy and building blocks they need to proliferate. Agilent Seahorse XF technology measures changes in both glycolytic and mitochondrial activity in real time, providing a window into the Warburg effect, substrate dependency, and other metabolic aspects of tumor cell biology.
July 2017 Volume 17 Number 7Advertisement
Nature Reviews Cancer cover
2016 2-year Impact Factor 37.147 Journal Metrics 2-year Median 28
In this issue
Research Highlights

Also this month
Article series:
Clinical insights
 Featured article:
Common pitfalls in preclinical cancer target validation
William G. Kaelin, Jr

Leukemia: Collection on Acute Myeloid Leukemia

AML is an area of focus for Leukemia and this collection brings together a number of recent key articles published in the journal. 

Access this collection free online for six months

Funded by a grant from Astex Pharmaceuticals, Inc. (a member of the Otsuka group)

Recommend to library
Take part in our PhD survey for your chance to win

Tell us what you love about life as PhD student, about your plans, and some of the challenges you face at this all-important career stage.

Take part in Nature Research Group's biennial global PhD survey, and you'll also have the chance to enter a prize draw to win a £100/$150 Amazon gift card.
A community map of cancer immunity

Immunotherapy is influenced by a complex set of tumour, host and environmental factors. Such factors combine to characterise the immunological status — or cancer-immune set point — of an individual.

Collaborate with peers to update, evolve and improve the cancer-immune set point framework
Advertisement webcasts

Springer Nature presents a custom webcast on: Integrated Molecular Profiling of Genitourinary Tumors:
Applications for Personalized Radiotherapy

Date: Wednesday, June 28, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST 

Register Free

Sponsored by: 
HTG Molecular Diagnostics, Inc.
Article series: Clinical insights
Comment: Melanoma: a global perspective
Raul Ossio, Rodrigo Roldán-Marín, Héctor Martínez-Said, David J. Adams & Carla Daniela Robles-Espinoza
p393 | doi:10.1038/nrc.2017.43
Most of our current knowledge of melanoma is derived from the study of patients from populations of European descent, for whom public health, sun protection initiatives and screening measures have appreciably decreased disease mortality. Notably, some melanoma subtypes that most commonly develop in other populations are not associated with exposure to ultraviolet (UV) light, suggesting a different disease aetiology. Further study of these subtypes is necessary to understand their risk factors and genomic architecture, and to tailor therapies and public health campaigns to benefit patients of all ethnic groups.
Abstract | Full Text | PDF | Supplementary information


Cancer models: Tailored mouse models
p395 | doi:10.1038/nrc.2017.45
To advance preclinical research, two groups have developed mouse models of metastatic colorectal cancer using the transplantation of engineered organoids.

Tumour immunology: LAP targeting reduces tolerogenic cells in cancer
p396 | doi:10.1038/nrc.2017.46
Anti-LAP antibodies show promising anticancer properties.

Immunotherapy: Macrophages steal the show
p396 | doi:10.1038/nrc.2017.47
Pittet and collaborators show that macrophages can remove anti-PD1 antibodies from T cells, blunting their response, whereas Weissman and colleagues demonstrate that macrophages also express PD1 on their surface, which impairs their phagocytic activity.

Leukaemia: Unravelling the heterogeneity of cancer stem cells
p397 | doi:10.1038/nrc.2017.44
Giustacchini, Thongjuea, et al. have developed a method to sensitively detect somatic mutations and analyze whole transcriptomes of the same single cell. Application of this technique to chronic myeloid leukaemia (CML) patient samples revealed heterogeneous CML stem cell populations with likely roles in CML progression and resistance to therapy.


Tumour metabolism: Losing that remaining fat | Cancer Models: Modeling clear cell renal cell carcinoma | Targeted therapies: Expanding the use of PARP inhibitors

JOBS of the week
Postdoctoral Position in Cancer Biology and / or Epigenetics
University of Pennsylvania
Post-doctoral Position in Cancer Genomics and Precision Medicine
Candiolo Cancer Institute-FPO, IRCCS
Postdoctoral Position in Cancer Genetics and Precision Oncology
Memorial Sloan Kettering Cancer Center (MSKCC)
Postdoctoral Scholar in Cancer Biology at the University of Chicago
University of Chicago
Postdoctoral Position in Ovarian Cancer Autophagy Research
Trevor G. Shepherd
More Science jobs from
NZBCS-2017: The New Zealand Breast Cancer Symposium
Auckland, NZ
More science events from
NEW JOURNAL! The Annual Review of Cancer Biology, Volume 1 is now available online, and reviews a range of subjects in cancer research representing important and emerging areas in the field. Free online access to this journal is available for six months with access code: CAONL2017.

Visit today to find out more
Imaging of anticancer drug action in single cells
Miles A. Miller & Ralph Weissleder
p399 | doi:10.1038/nrc.2017.41
This Review summarizes developments in the imaging of in vivo anticancer drug action, with a focus on microscopy approaches at the single-cell level and translational lessons for the clinic.
Abstract | Full Text | PDF | Supplementary information

Transposable elements in cancer
Kathleen H. Burns
p415 | doi:10.1038/nrc.2017.35
Long interspersed element-1 (LINE-1) transposable elements are active in the human genome. In this Review, Burns describes how the retrotransposition activity of LINE-1 in cancer genomes can result in somatically acquired insertions that mark evolving tumour clones.
Abstract | Full Text | PDF

Turning the tide in myelodysplastic/myeloproliferative neoplasms
Michael W. N. Deininger, Jeffrey W. Tyner & Eric Solary
p425 | doi:10.1038/nrc.2017.40
This Review describes our current understanding of the relationship between genotype and phenotype in myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) and discusses how this knowledge could be used to inform strategies to develop more effective treatments and improve clinical success.
Abstract | Full Text | PDF | Supplementary information
Common pitfalls in preclinical cancer target validation
William G. Kaelin, Jr
p425 | doi:10.1038/nrc.2017.32
This Perspective discusses some of the causes of the robustness and reproducibility problem in preclinical cancer research and suggests solutions.
Abstract | Full Text | PDF

Premium Quality Monoclonal Isotype Controls – Ideal for In Vivo Studies and Standard Immunoassays
CrownBio's in vivo grade human, mouse, rabbit and rat isotype control antibodies are formulated with:
  • Very low endotoxin levels (<0.5 EU/mg)
  • Supplied at high concentration (2-5 mg/ml)
  • Supplied in PBS only; no carriers or additives
  • 95% purity as analyzed by SDS-PAGE and HPLC
>> Download our Isotype Control Application Note
Call for nominations: 2017 John Maddox Prize for Standing up for Science.

Recognising the work of individuals who promote science in the face of hostility. Winners will be announced at a reception in London, as well as in Nature, and will receive £2,000.

Closing date for nominations is 31st July 2017.

Click to learn more
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at:
(You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: